Pharmacological targeting of endoplasmic reticulum stress in disease

SJ Marciniak, JE Chambers, D Ron - Nature reviews Drug discovery, 2022 - nature.com
The accumulation of misfolded proteins in the endoplasmic reticulum (ER) leads to ER
stress, resulting in activation of the unfolded protein response (UPR) that aims to restore …

Lysosomes as a therapeutic target

SR Bonam, F Wang, S Muller - Nature reviews Drug discovery, 2019 - nature.com
Lysosomes are membrane-bound organelles with roles in processes involved in degrading
and recycling cellular waste, cellular signalling and energy metabolism. Defects in genes …

Lysosomal storage diseases

FM Platt, A d'Azzo, BL Davidson, EF Neufeld… - Nature reviews Disease …, 2018 - nature.com
Lysosomal storage diseases (LSDs) are a group of over 70 diseases that are characterized
by lysosomal dysfunction, most of which are inherited as autosomal recessive traits. These …

[HTML][HTML] Fabry disease revisited: management and treatment recommendations for adult patients

A Ortiz, DP Germain, RJ Desnick, J Politei… - Molecular genetics and …, 2018 - Elsevier
Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA
gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life …

Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology

PM Seferović, M Polovina, J Bauersachs… - European journal of …, 2019 - Wiley Online Library
Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important
cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural …

The rapidly evolving view of lysosomal storage diseases

G Parenti, DL Medina, A Ballabio - EMBO molecular medicine, 2021 - embopress.org
Lysosomal storage diseases are a group of metabolic disorders caused by deficiencies of
several components of lysosomal function. Most commonly affected are lysosomal …

Drug development in the era of precision medicine

SA Dugger, A Platt, DB Goldstein - Nature reviews Drug discovery, 2018 - nature.com
For the past three decades, the use of genomics to inform drug discovery and development
pipelines has generated both excitement and scepticism. Although earlier efforts …

[HTML][HTML] Treatment of Fabry's disease with the pharmacologic chaperone migalastat

DP Germain, DA Hughes, K Nicholls… - New england journal …, 2016 - Mass Medical Soc
Background Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency,
leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic …

An expert consensus document on the management of cardiovascular manifestations of Fabry disease

A Linhart, DP Germain, I Olivotto… - European journal of …, 2020 - Wiley Online Library
Fabry disease (FD) is an X‐linked lysosomal storage disorder caused by pathogenic
variants in the α‐galactosidase A (GLA) gene that leads to reduced or undetectable α …

Emptying the stores: lysosomal diseases and therapeutic strategies

FM Platt - Nature reviews Drug discovery, 2018 - nature.com
Lysosomal storage disorders (LSDs)—designated as' orphan'diseases—are inborn errors of
metabolism caused by defects in genes that encode proteins involved in various aspects of …